Phase 2 EGFR Gene Mutation Clinical Trials
6 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–6 of 6 trials
Recruiting
Phase 2
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital25 enrolled1 locationNCT07548060
Recruiting
Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224
Recruiting
Phase 2
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
Non-Small-Cell Lung CarcinomaEGFR Gene MutationAdvanced Non-Small Cell Squamous Lung Cancer
The Netherlands Cancer Institute16 enrolled1 locationNCT06222489
Recruiting
Phase 1Phase 2
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Gene Mutation
China Medical University Hospital20 enrolled1 locationNCT06071013
Recruiting
Phase 2
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Non-small Cell Lung CancerALK Gene MutationEGFR Gene Mutation+2 more
Hunan Province Tumor Hospital6,000 enrolled1 locationNCT04322890
Recruiting
Phase 2
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
Lung Adenocarcinoma Stage IIILung Adenocarcinoma Stage IVEGFR Gene Mutation
Shanghai Pulmonary Hospital, Shanghai, China96 enrolled1 locationNCT05503667